Pictet Asset Management SA lifted its stake in shares of Chimerix, Inc. (NASDAQ:CMRX – Get Rating) by 109.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 662,104 shares of the biopharmaceutical company’s stock after purchasing an additional 346,224 shares during the period. Pictet Asset Management SA owned 0.76% of Chimerix worth $1,377,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in CMRX. Monaco Asset Management SAM acquired a new position in shares of Chimerix during the 2nd quarter worth approximately $3,077,000. Philosophy Capital Management LLC acquired a new position in Chimerix in the first quarter valued at approximately $2,888,000. State Street Corp lifted its holdings in Chimerix by 14.2% in the first quarter. State Street Corp now owns 4,561,868 shares of the biopharmaceutical company’s stock valued at $20,893,000 after acquiring an additional 568,498 shares during the last quarter. Walleye Capital LLC acquired a new position in Chimerix in the second quarter valued at approximately $863,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Chimerix by 74.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 623,668 shares of the biopharmaceutical company’s stock valued at $1,297,000 after acquiring an additional 266,195 shares during the last quarter. 63.43% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Chimerix
In other news, Director Fred A. Middleton bought 20,000 shares of the business’s stock in a transaction on Thursday, September 29th. The shares were bought at an average price of $1.86 per share, with a total value of $37,200.00. Following the completion of the transaction, the director now directly owns 40,000 shares in the company, valued at $74,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 8.20% of the stock is owned by corporate insiders.
Chimerix Stock Up 0.5 %
Wall Street Analyst Weigh In
CMRX has been the topic of a number of recent analyst reports. StockNews.com upgraded Chimerix from a “hold” rating to a “buy” rating in a report on Friday, November 4th. Capital One Financial initiated coverage on Chimerix in a report on Wednesday, September 7th. They issued an “overweight” rating and a $7.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $8.50.
Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
- Get a free copy of the StockNews.com research report on Chimerix (CMRX)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.